非典型小腺泡增生在前列腺穿刺病理中的临床意义  

Clinical significance of atypical small acinar proliferation in prostate biopsy

作　　者：王浩 谢大炜 王思琦 吴栗洋 杨朴深 何威峰 王建文[1] WANG Hao;XIE Dawei;WANG Siqi;WU Liyang;YANG Pushen;HE Weifeng;WANG Jianwen(Department of Urology,Beijing Chaoyang Hospital Affiliated to Capital Medical University,Beijing,100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院泌尿外科,北京100020

出　　处：《临床泌尿外科杂志》2023年第8期636-640,共5页Journal of Clinical Urology

基　　金：首都卫生发展科研专项项目(No:首发2020-2-2033)。

摘　　要：前列腺癌(prostate cancer,PCa)是男性泌尿生殖系统中最为常见的恶性肿瘤之一,前列腺穿刺是目前诊断PCa的金标准。非典型小腺泡增生(atypical small acinar proliferation,ASAP)在穿刺病理报告中并不少见,表现为疑似癌却又不能确定为癌的一种病理现象。但目前ASAP对发展为有临床意义的PCa风险作用尚不清楚,对于立即或推迟再次活检缺少共识。本文就ASAP病理学特征、对PCa的预测因素、预测概率和再活检作综述,以指导泌尿外科医生作出最佳决策。Prostate cancer(PCa)is one of the most common malignancies of the male urogenital system.Prostate biopsy is the gold standard for the diagnosis of PCa.Atypical small acinar proliferation(ASAP)is not uncommon and considered as suspicious atypical foci,but it is not diagnostic for malignancy.However,the role of ASAP on the risk of developing clinically significant PCa is currently unclear and there is no consensus about the best strategy:immediate versus deferred re-biopsy.In this review,we will summarize the characteristics of ASAP pathology,the predictive factors for PCa and re-biopsy strategy to guide urological surgeons in making optimal decisions.

关 键 词：非典型小腺泡增生 前列腺癌 穿刺活检 重复活检 

分 类 号：R737.25[医药卫生—肿瘤]